Prosecution Insights
Last updated: April 19, 2026

Examiner: TRAN, KHOA NHAT

Tech Center 1600 • Art Units: 1632

This examiner grants 33% of resolved cases

Performance Statistics

32.8%
Allow Rate
-27.2% vs TC avg
133
Total Applications
+63.7%
Interview Lift
1410
Avg Prosecution Days
Based on 58 resolved cases, 2023–2026

Rejection Statute Breakdown

8.5%
§101 Eligibility
14.7%
§102 Novelty
43.6%
§103 Obviousness
30.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17426467 RNA-TARGETING CAS ENZYMES Non-Final OA The Regents of the University of California
17262460 Treatment of Vascular Occlusion by Activation of Notch Signaling Non-Final OA The Regents of the University of California
17842715 CULTURE SYSTEM AND METHODS FOR IMPROVED MODELING OF NEUROLOGICAL CONDITIONS Final Rejection Genentech, Inc.
17616283 APPLICATION OF ANTIARRHYTHMIC AGENTS TO STEM CELL DERIVED CARDIOMYOCYTES AND USES THEREOF Final Rejection Novo Nordisk A/S
17424529 IN VITRO HUMAN BLOOD BRAIN BARRIER Non-Final OA Massachusetts Institute of Technology
17250791 METHODS OF CULTURING PODOCYTES AND COMPOSITIONS THEREOF Non-Final OA Beth Israel Deaconess Medical Center, Inc.
17802577 PRODUCTION METHOD OF RETINAL PIGMENT EPITHELIAL CELL Non-Final OA RIKEN
17048289 INDUCTION OF MYELINATING OLIGODENDROCYTES IN HUMAN CORTICAL SPHEROIDS Final Rejection Case Western Reserve University
17738843 EX VIVO TISSUE EXPLANT AND GRAFT PLATFORM AND USES THEREOF Non-Final OA The Brigham and Women's Hospital, Inc.
17430131 GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED ARTIFICIAL TISSUE STRUCTURES WITHOUT THREE DIMENSIONAL MATRICES Non-Final OA MILTENYI BIOTEC B.V. & CO. KG
17863785 HIGH-DENSITY CELL CULTURE METHOD Final Rejection AJINOMOTO CO., INC.
17610124 EXTRACELLULAR MATRIX MATERIAL AND USES THEREOF Non-Final OA The Chinese University of Hong Kong
18171832 METHOD OF PRODUCING CONDITIONED MEDIUM FOR CULTURING PATIENT-DERIVED CANCER CELLS Non-Final OA TOPPAN Inc.
17924687 INDIRECT SELECTIVE BREEDING METHOD OF HIGH-COLLAGEN MEAT GEESE Non-Final OA YANGZHOU UNIVERSITY
18757662 Renal Progenitor Cells Non-Final OA The University of Queensland
17611241 HIGH CONCENTRATION CELL PACKAGING AND SHIPPING Non-Final OA Rutgers, The State University of New Jersey
17272204 MEDIUM COMPOSITION FOR SUSPENSION CULTURE OF ADHESIVE CELLS Final Rejection NISSAN CHEMICAL CORPORATION
17310007 FIBROBLAST REGENERATIVE CELLS Non-Final OA Figene, LLC
17309649 THERAPEUTIC USES OF GENE EDITED FIBROBLASTS Non-Final OA Figene, LLC
17052859 PAIN-REDUCING EFFECTS OF FIBROBLASTS AND TREATMENT OF PAIN Final Rejection Figene, LLC
18028156 MINI-BRAIN STRUCTURE AND CONSTRUCTION METHOD THEREFOR Non-Final OA SOGANG UNIVERSITY RESEARCH & BUSINESS DEVELOPMENT FOUNDATION
17606644 SYNTHETIC SELF-REPLICATING RNA VECTORS ENCODING CRISPR PROTEINS AND USES THEREOF Non-Final OA EMD Millipore Corporation
17440081 CARDIOMYOCYTE PROLIFERATION Final Rejection The Council of the Queensland Institute of Medical Research
17421161 System and method for cryopreservation of tissues Non-Final OA THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE
17779275 METHODS OF REPROGRAMMING A CELL Final Rejection MONASH UNIVERSITY
17436374 POROUS CELLULAR SCAFFOLD COMPRISING SERUM-DERIVED PROTEIN, AND PRODUCTION METHOD THEREFOR Non-Final OA DANAGREEN CO., LTD.
17501716 PORCINE SEXED SEMEN AND METHODS OF USE Final Rejection ABS Global, Inc.
17273143 BIOMATERIAL COMPRISING ADIPOSE-DERIVED STEM CELLS AND GELATIN AND METHOD FOR PRODUCING THE SAME Non-Final OA NOVADIP BIOSCIENCES
17605714 TREATMENT OF KIDNEY DISEASE IN SUBJECTS WITH KIDNEY AND/OR URINARY TRACT ANOMALIES Non-Final OA ProKidney
18195223 COLD PLASMA TREATMENT MEDIATED TUMOR SPECIFIC T CELL THERAPY Non-Final OA Jerome Canady Research Institute for Advanced Biological and Technological Sciences

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month